KCT0008301招募中Unknown
Clinical Research of Anti-Tumor Activity and Safety of Autologous Vax-NK/HCC Consolidation Therapy Following First- line Chemoimmunotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Chonnam National University Hospital Hwasun Hospital0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 100(Year)（—）
- 性别
- All
入选标准
- •1) Patients who are histologically or cytologically confirmed to have extensive stage small cell lung cancer.
- •2) Patients with no tumor progression observed after 4 cycles of the first-line chemoimmunotherapy (ACE regimen)
- •3) an adult over the age of 19
- •4) Patients with ECOG performance score below 2
- •5) Patients who have signed and agreed to participate in this clinical study
- •6) A patient who has obtained a consent form for donation to the Biobank of Chonnam National University Hwasun Hospital
- •7) Patients who meet the following conditions in a blood test.
- •- Absolute neutrophil count (ANC) = 1.0 x 10^9/L
- •- White blood cells count (WBC) = 3.0 x 10^9/L
- •- Serum bilirubin = 2.5 x Normal range
- •- AST and ALT = 2.5 × Normal Range
排除标准
- •1) Patients who are not histologically or cytologically small cell lung cancer
- •2) Patients observed progression of disease after 2 cycles of first-line chemoimmunotherapy (ACE regimen)
- •3) Patients who have not completed primary ACE regimen up to 4 cycles
- •4) Untreated active brain or central nervous system metastasis
- •5) Uncontrolled cardiovascular disease (e.g., myocardial infarction and unstable angina within 3 months)
- •6) an uncontrolled, active infectious disease
- •7) a patient with autoimmune disease
- •8) Pregnant women, lactating women, or pregnant women who do not use proper contraception.
研究者
相似试验
已完成
不适用
Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer.Cisplatin-resistant urothelial cancerJPRN-UMIN000010957agasaki University Hospital15
进行中（未招募）
1 期
Selinexor in the treatment of patients with Refractory and/or Relapsed Richter's TransformatioEUCTR2014-001240-38-GBKaryopharm Therapeutics Inc.50
进行中（未招募）
1 期
Richters TransformatioInitial and Refractory/Relapsed Richters Transformation (RT)MedDRA version: 18.0Level: PTClassification code 10058728Term: Richter's syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001240-38-DEKaryopharm Therapeutics, Inc.50
进行中（未招募）
1 期
Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor CancerAdvanced Colorectal cancer (CRC), pancreatic cancer or non-small cell lung cancer (NSCLC), and other indications dependent on emerging dataMedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033604EUCTR2016-001080-36-DEAmgen Incorporated197
进行中（未招募）
1 期
Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor CancerAdvanced Colorectal cancer (CRC), pancreatic cancer or non-small cell lung cancer (NSCLC), and other indications dependent on emerging dataMedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033604EUCTR2016-001080-36-BEAmgen Incorporated197